-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-08-27
The reference study shows that kinase inhibitors can do more than block p38α catalytic activity: selected compounds also expose the activation-loop phospho-threonine and accelerate its removal by WIP1. By combining biochemical dephosphorylation assays with X-ray crystallography, the work establishes kinase conformation as a potential lever for improving inhibitor specificity, durability, and pathway control.
-
MK-1775: Wee1 Kinase Inhibitor Workflow
2026-08-27
Use MK-1775 to interrogate Wee1-dependent checkpoint control, then separate growth arrest from true cell killing with orthogonal readouts. This workflow is especially useful for testing DNA-damage combinations in p53-deficient models without overinterpreting a single viability endpoint.
-
Multiple Myeloma Cell Lines: Mutations and Drug Response
2026-08-26
Vikova and colleagues used whole-exome sequencing across a genetically diverse panel of human multiple myeloma cell lines to define recurrent coding mutations, altered pathways, and links to drug response. The study provides a practical framework for selecting cell-line models and developing hypotheses about disease progression and treatment resistance.
-
BOP Reagent Workflow for Peptide and Prodrug Synthesis
2026-08-26
BOP reagent supports controlled carboxyl group activation for amide bond formation, phenyl ester preparation, and blocked amino acid derivative workflows. This article connects practical coupling design with the carrier-free triterpene prodrug strategy reported for oral squamous cell carcinoma, while clearly separating established chemistry from forward-looking applications.
-
G007-LK: From Tankyrase Biology to Translation
2026-08-25
G007-LK is a selective tankyrase 1/2 inhibitor that connects TNKS1/2 enzymatic control with AXIN stabilization, β-catenin degradation induction, and Hippo pathway modulation. This thought-leadership guide helps translational researchers design stronger mechanistic studies across APC mutation colorectal cancer research and hepatocellular carcinoma models while keeping pharmacologic and clinical limitations in view.
-
Tetrandrine Workflows for Ion Channel Research
2026-08-25
Build reproducible Tetrandrine assays for calcium-channel signaling, inflammation, and cancer biology research with practical stock-preparation and troubleshooting guidance. The workflow also shows how to distinguish membrane-targeted experiments from computational natural-product screening claims.
-
RNA Clean and Concentrator Kit: Workflow Guide
2026-08-24
The RNA Clean and Concentrator Kit is a membrane-based RNA purification spin column workflow for rapid cleanup of RNA from enzymatic reactions. The K1069 format is optimized for single-stranded RNA longer than 100 nucleotides and double-stranded RNA longer than 200 base pairs across a stated recovery range of 1 ng to 500 μg.
-
Saquinavir in HIV Protease and Permeability Workflows
2026-08-24
Saquinavir combines a well-defined antiviral mechanism with a useful test case for enzyme, membrane-interaction, and MS-compatible permeability workflows. This guide shows how to connect HIV protease inhibition with biomimetic IAM-LC and OT-CEC assays while separating established evidence from method-development recommendations.
-
Masitinib (AB1010): KIT/PDGFR Research Guide
2026-08-23
Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for selective KIT, PDGFRα, and PDGFRβ pathway studies. It is appropriate for defined cancer, mast cell, and inflammatory research workflows, but not for aqueous or ethanol-based assays, broad-spectrum kinase profiling, or clinical treatment decisions.
-
GSK 2837808A for LDHA Metabolism Workflows
2026-08-22
GSK 2837808A is a potent, selective LDHA inhibitor for connecting lactate production with glucose use in cancer-cell assays. This workflow shows how to control exposure, quantify metabolic effects, and interpret results alongside the NAT1–ENO1–lactate pathway described in colorectal cancer research.
-
DDI2–NFE2L1 Signaling Protects Against Ferroptosis
2026-08-22
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive proteostasis response to ferroptosis. By integrating site-specific ubiquitylation proteomics, genetic perturbation, and chemical inhibition, it shows that disrupting this pathway weakens proteasome recovery and increases susceptibility to oxidative cell death.
-
Drug Response Assays: Growth Inhibition Versus Cell Death
2026-08-21
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to show that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer drug response. Its practical contribution is a more careful in vitro framework: researchers should consider response magnitude, composition, and timing rather than treating a single viability endpoint as direct evidence of cell death.
-
EGCG Workflows for Apoptosis and Neuroprotection
2026-08-20
Build reproducible EGCG experiments around concentration-response design, orthogonal readouts, and careful separation of purified-compound effects from complex food matrices. This workflow connects apoptosis assay development, cancer chemoprevention, antiviral research, and neurodegeneration models without overstating what any single system proves.
-
KX2-391 dihydrochloride Research Workflows
2026-08-20
KX2-391 dihydrochloride enables coordinated interrogation of Src signaling, tubulin polymerization, HBV transcription, and BoNT/A activity. This workflow-focused guide covers assay setup, concentration selection, cross-domain interpretation, and practical troubleshooting.
-
6-Thioguanine Blocks EV71 via BIRC3-Linked Autophagy
2026-08-19
The 2025 BMC Microbiology study identifies 6-thioguanine as a potent in vitro inhibitor of Enterovirus 71 replication and links this activity to reduced BIRC3 expression and attenuated complete autophagy. Its high selectivity index in HT-29 cells supports further antiviral investigation, while the cell-based design and lack of in vivo validation require cautious interpretation.